8-K: SELLAS Reports Strong Cash, Advances AML Trials

SELLAS Life Sciences announced full-year 2025 financial results, reporting a strong cash position and significant progress in its pivotal Phase 3 REGAL trial and SLS009 clinical programs for AML.

Summary

• Reported full year 2025 financial results and provided a corporate update.
• Continued advancement of the pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML), with final analysis upon reaching 80 events; 72 events were recorded as of December 26, 2025.
• Dosed the first patient in a Phase 2 trial of SLS009 in newly diagnosed first-line AML patients.
• Presented positive Phase 2 data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025, showing a 46% overall response rate (CR/Cri/MLFS) among 35 evaluable patients, including 29% achieving CR/CRi, and a median overall survival (mOS) of 8.9 months in the least pretreated cohort.
• Held $71.8 million in cash and cash equivalents as of December 31, 2025.
• Received an additional $42.6 million in proceeds in Q1 2026 to date through warrant exercises.
• Entered into a strategic collaboration with IMPACT-AML in January 2026 to expand the SLS009 clinical program in Europe, with enrollment of approximately 40 patients anticipated in Q2 2026.
• Preclinical data on SLS009 in AML, demonstrating induction of apoptosis in AML cell lines, will be presented at AACR on April 21, 2026.
• Preclinical data on SLS009 in T-PLL presented at ESMO 2025 showed a statistically significant survival benefit.
• Hosted a virtual R&D Day on October 29, 2025, focusing on advancing novel therapies in AML.
• Received $67.2 million in gross proceeds from warrant exercises during 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by significant clinical progress in both lead programs, particularly the encouraging Phase 2 data for SLS009 and the nearing completion of the pivotal REGAL trial, coupled with a substantially strengthened financial position.

Positives

• Achieved a strong cash position with $71.8 million as of December 31, 2025, further bolstered by an additional $42.6 million from warrant exercises in Q1 2026, marking the strongest financial position in company history.
• Reported positive Phase 2 data for SLS009 in r/r AML, demonstrating a 46% overall response rate and a median overall survival of 8.9 months in the least pretreated cohort, which is significantly higher than the expected 2.6 months.
• Expanded the SLS009 development program into earlier-line AML treatment, with the first patient dosed in a newly diagnosed AML trial, following constructive feedback from the FDA.
• Advanced the pivotal Phase 3 REGAL trial for GPS, nearing final analysis with 72 out of 80 required events recorded.
• Established a strategic collaboration with IMPACT-AML to expand the SLS009 clinical program in Europe, with enrollment of approximately 40 patients anticipated in Q2 2026.
• Presented preclinical data for SLS009 showing statistically significant survival benefit in T-PLL and induction of apoptosis in AML cell lines.
• Reduced net loss to $26.9 million for the year ended December 31, 2025, compared to $30.9 million for the prior year.
• Decreased Research and Development expenses to $16.0 million in 2025 from $19.1 million in 2024.
• Decreased General and Administrative expenses to $12.3 million in 2025 from $12.4 million in 2024.

Negatives

• Continued to report a net loss of $26.9 million for the year ended December 31, 2025.

Risks

• Risks and uncertainties are inherent in oncology product development and clinical success.
• There is uncertainty regarding regulatory approval for product candidates.
• Other risks and uncertainties affecting SELLAS and its development programs are detailed under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 19, 2026, and in its other SEC filings.
• Other risks and uncertainties of which SELLAS is not currently aware may also affect forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

Future Outlook

SELLAS anticipates 2026 to be a pivotal year, with the final analysis of the Phase 3 REGAL trial expected upon reaching 80 events, which could position GPS as a firstand best-in-class immunotherapeutic option in AML. The company also expects continued significant progress in its SLS009 clinical program, including expansion into earlier treatment settings and European collaboration, with a catalyst-rich outlook.

Management Comments

• "Based upon continued progress in our GPS and SLS009 clinical programs in AML, we believe 2026 is shaping up to be a pivotal year for SELLAS." Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer.
• "We are advancing toward the final analysis of our Phase 3 REGAL trial evaluating GPS in AML patients who have achieved complete remission following second-line salvage therapy. Once we reach the required pre-specified 80th event, which will be announced, we will proceed with the necessary procedures towards database lock completion, statistical analysis, unblinding, and disclosure of topline results." Angelos Stergiou, MD, ScD h.c.
• "If positive, REGAL could position GPS as a firstand best-in-class immunotherapeutic option in this AML population and serve as a significant value-inflection point for SELLAS." Angelos Stergiou, MD, ScD h.c.
• "We also continue to make significant progress in our SLS009 clinical program for AML. Following the positive Phase 2 results of SLS009 in r/r AML presented at ASH, particularly in high-risk molecular subtypes, we have now dosed the first patient in the expansion cohort, which is evaluating SLS009 in newly diagnosed, first-line AML patients." Angelos Stergiou, MD, ScD h.c.
• "With a catalyst rich outlook, continued clinical execution, our strongest financial position in history and expansion into earlier treatment settings, we look forward to an important year ahead." Angelos Stergiou, MD, ScD h.c.

Industry Context

StockSavvy.ai notes that the focus on Acute Myeloid Leukemia (AML) and T-cell prolymphocytic leukemia (T-PLL) positions SELLAS within a high-need oncology market. The development of novel immunotherapies like GPS and CDK9 inhibitors like SLS009 addresses critical unmet needs, particularly for relapsed/refractory patients and those with high-risk molecular subtypes, aligning with broader industry trends towards targeted and combination therapies. The collaboration with IMPACT-AML for European expansion reflects a common strategy for biopharmaceutical companies to accelerate clinical development and market access.

Comparison to Industry Standards

• The median overall survival (mOS) of 8.9 months for SLS009 in the least pretreated r/r AML cohort is exceedingly higher than the expected 2.6 months in this patient population, indicating a significant improvement over current benchmarks for this difficult-to-treat group.
• The 46% overall response rate (CR/Cri/MLFS) for SLS009 in r/r AML patients, including 29% achieving CR/CRi, compares favorably to historical response rates in this heavily pretreated population, which often sees lower single-digit response rates with standard salvage therapies.
• The safety profile of SLS009, with no dose-limiting toxicities (DLTs) or treatment-related deaths observed, suggests a potentially better tolerability profile compared to some existing AML treatments that can have significant side effects.

Stakeholder Impact

• Shareholders: Potential for significant value inflection if REGAL trial results are positive; strengthened financial position reduces immediate dilution risk; positive clinical data could increase investor confidence.
• Patients (AML/T-PLL): Potential for new, effective treatment options, especially for relapsed/refractory and high-risk AML patients, and those with T-PLL.
• Employees: Continued progress and financial stability suggest job security and potential for growth.
• Regulatory Authorities: Continued engagement with the FDA (constructive feedback received for SLS009 expansion) indicates an ongoing regulatory pathway.
• Partners (IMPACT-AML): Collaboration expands clinical reach and potential for future commercialization.

Next Steps

• Final analysis of the Phase 3 REGAL trial upon reaching the 80th event, followed by database lock, statistical analysis, unblinding, and disclosure of topline results.
• Enrollment of approximately 40 patients in Europe for the SLS009 clinical program in combination with AZA/VEN in newly diagnosed AML patients, anticipated in Q2 2026.
• Presentation of preclinical data on SLS009 in AML at the 2026 American Association for Cancer Research (AACR) on April 21, 2026.
• Continued development of SLS009 in newly diagnosed first-line AML patients.

Key Dates

Recommendation

The filing presents a highly positive outlook for SELLAS, driven by significant clinical advancements and a robust financial position. The Phase 3 REGAL trial is nearing its critical 80-event milestone, with positive results having the potential to be a major value inflection point. The SLS009 program shows compelling Phase 2 data in a challenging r/r AML population, exceeding expectations for overall survival, and is expanding into earlier treatment lines. The substantial increase in cash and cash equivalents, bolstered by recent warrant exercises, provides a strong runway for continued development without immediate capital concerns. These factors collectively suggest a strong potential for future growth and warrant a "strong buy" recommendation for investors seeking exposure to innovative oncology therapeutics.

Keywords

SELLAS Life Sciences, SLS, AML, Acute Myeloid Leukemia, GPS, Galinpepimut-S, SLS009, Tambiciclib, CDK9 inhibitor, REGAL trial, Phase 3, Phase 2, oncology, biopharmaceutical, cancer, clinical trial, financial results, cash position, warrant exercise, ASH, ESMO, AACR, T-PLL, myelodysplastic syndrome, ASXL1 mutation, TP53 mutation